Neurochemical Research

, Volume 34, Issue 2, pp 234–237 | Cite as

Thalamo-Basal Ganglia Connectivity in Postmenopausal Women Receiving Estrogen Therapy

  • Heather A. Kenna
  • Natalie L. RasgonEmail author
  • Cheri Geist
  • Gary Small
  • Daniel Silverman
Original Paper


Cumulative data on the effects of estrogen therapy (ET) on brain function in postmenopausal women suggests that ET influences cerebral metabolism and may protect against age-related declines in various domains of cognitive function. The beneficial cognitive effects of ET may relate to its modulation of the thalamic-striatum cholinergic and dopaminergic systems, as the activity of both neurotransmitter systems in the thalamus appears to be positively influenced by estrogen. In the current study, we attempted to evaluated regional cerebral brain metabolism utilizing [18F]-fluorodeoxyglucose positron emission tomography in 11 healthy recently-postmenopausal women on ET (ET+) in comparison to 11 recently-postmenopausal and ET-naïve women (ET−) in order to assess the effects of ET on cholinergic and dopaminergic system regulation. Results showed thalamo-basal ganglia connectivity among ET+ women but not among ET− women. The presence of connectivity in the thalamo-striatal pathway in recently postmenopausal women suggests estrogen effects in preserving integrity of the cholinergic and dopaminergic systems. The results also suggest that ET initiated at or near the menopausal transition may modulate brain aging by mediating complex sensory-motor functions.


Estrogen Connectivity Brain Menopause Cholinergic Dopaminergic 



Dr. Rasgon has received Grant/Research Support from Abbott, Forest, GlaxoSmithKline, and Wyeth-Ayerst. She was on advisory boards for GlaxoSmithKline and Wyeth-Ayerst, and has received currently or in the past Speaker Honorarium from Abbott, Bristol Myers Squibb, Forest, GlaxoSmithKline, and Pfizer. The University of California, Los Angeles, owns a U.S. patent (6,274,119) entitled “Methods for Labeling b-Amyloid Plaques and Neurofibrillary Tangles,” which has been licensed to Siemens. Dr. Small is among the inventors, has received royalties, and will receive royalties on future sales. Dr. Small served as a consultant and has received Speaker Honorarium from Abbott, Brainstorming Co., Dakim, Eisai, Forest, Myriad Genetics, Novartis, Ortho-McNeil, Pfizer, Radica, Servier, and Siemens. Dr. Small also has received stock options from Dakim.


  1. 1.
    Rasgon N, Silverman D, Siddarth P et al (2005) Estrogen use and brain metabolic change in postmenopausal women. Neurobiol Aging 26:229–235PubMedCrossRefGoogle Scholar
  2. 2.
    Rasgon N, Small G, Giddarth P et al (2001) Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatry Res 107:11–18PubMedCrossRefGoogle Scholar
  3. 3.
    Maki P, Resnick S (2001) Effects of estrogen on patterns of brain activity at rest and during cognitive activity: a review of neuroimaging studies. Neuroimage 14:789–801PubMedCrossRefGoogle Scholar
  4. 4.
    Norbury R, Cutter W, Compton J et al (2003) The neuroprotective effects of estrogen on the aging brain. Exp Gerontol 38:109–117PubMedCrossRefGoogle Scholar
  5. 5.
    Halbreich U, Lumley L, Palter S et al (1995) Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 29:153–163PubMedCrossRefGoogle Scholar
  6. 6.
    Kimura M, Minamimoto T, Matsumoto N et al (2004) Monitoring and switching of cortico-basal ganglia loop functions by the thalamo-striatal system. Neurosci Res 48:355–360PubMedCrossRefGoogle Scholar
  7. 7.
    Cornwall J, Phillipson O (1988) Afferent projections to the dorsal thalamus of the rat as shown by retrograde lectin transport—I. The mediodorsal nucleus. Neuroscience 24:1035–1049PubMedCrossRefGoogle Scholar
  8. 8.
    Cornwall J, Phillipson O (1988) Afferent projections to the dorsal thalamus of the rat as shown by retrograde lectin transport. II. The midline nuclei. Brain Res Bull 21:147–161PubMedCrossRefGoogle Scholar
  9. 9.
    McKinney M, Jacksonville M (2005) Brain cholinergic vulnerability: relevance to behavior and disease. Biochem Pharmacol 70:1115–1124PubMedCrossRefGoogle Scholar
  10. 10.
    García-Cabezas M, Rico B, Sánchez-González M et al (2007) Distribution of the dopamine innervation in the macaque and human thalamus. Neuroimage 34:965–984PubMedCrossRefGoogle Scholar
  11. 11.
    Cropley V, Fujita M, Innis R et al (2006) Molecular imaging of the dopamergic system and its association with human cognitive function. Biol Psychiatry 59:898–907PubMedCrossRefGoogle Scholar
  12. 12.
    Kipp M, Karakaya S, Pawlak J et al (2006) Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. Front Neuroendocrinol 27:376–390PubMedCrossRefGoogle Scholar
  13. 13.
    Dluzen D, Horstink M (2003) Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 21(1):67–75PubMedCrossRefGoogle Scholar
  14. 14.
    Das A, Dikshit M, Srivastava S et al (2002) Effect of ovariectomy and estrogen supplementation on brain acetylcholinesterase activity and passive-avoidance learning in rats. Can J Pharm 80:907–914CrossRefGoogle Scholar
  15. 15.
    Norbury R, Travis M, Erlandsson K et al (2007) Estrogen therapy and brain muscarinic receptor density in healthy females: a SPET study. Horm Behav 51:249–257PubMedCrossRefGoogle Scholar
  16. 16.
    Dumas J, Hancur-Bucci C, Naylor M et al (2008) Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis. Horm Behav 53:159–169PubMedCrossRefGoogle Scholar
  17. 17.
    Bosse R, DiPaolo T (1996) The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occuring at menopause. Cell Mol Neurobiol 16:199–212PubMedCrossRefGoogle Scholar
  18. 18.
    Byrnes E, Bridges R (2007) Reproductive experience and expression of dopamine D(2) receptor mRNA: a possible mechanism for reduced prolactin secretion in primiparous rats. J Neuroendocrinol 19:773–778PubMedCrossRefGoogle Scholar
  19. 19.
    Friston K, Holmes A, Worsley K et al (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189–210CrossRefGoogle Scholar
  20. 20.
    Friston K, Ashburner J, Frith C et al (1995) Spatial registration and normalisation of images. Hum Brain Mapp 2:165–189CrossRefGoogle Scholar
  21. 21.
    Gibbs R, Aggarwal P (1998) Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer’s disease-related cognitive decline. Horm Behav 34:98–111PubMedCrossRefGoogle Scholar
  22. 22.
    Tinkler G, Voytko M (2005) Estrogen modulates cognitive and cholinergic processes in surgically menopausal monkeys. Prog Neuro-Psychopharmacol Biol Psychiatry 29:423–431CrossRefGoogle Scholar
  23. 23.
    Voytko M (2002) Estrogen and the cholinergic system modulate visuospatial attention in monkeys. Behav Neurosci 116:187–197PubMedCrossRefGoogle Scholar
  24. 24.
    Dumas J, Hancur-Bucci C, Naylor M et al (2006) Estrogen-treatment effects on anticholinergic-induced cognitive dysfunction in normal post-menopausal women. Neuropsychopharmacology 31:2065–2078PubMedCrossRefGoogle Scholar
  25. 25.
    Henderson V, Espeland M, Hogan P et al (2007) Prior use of hormone therapy and incident Alzheimer’s disease in the Women’s Health Initiative Memory Study. Neurology 68:A205CrossRefGoogle Scholar
  26. 26.
    Rossouw J, Prentice R, Manson J et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–1477PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Heather A. Kenna
    • 1
  • Natalie L. Rasgon
    • 1
    Email author
  • Cheri Geist
    • 2
  • Gary Small
    • 2
  • Daniel Silverman
    • 3
  1. 1.Department of Psychiatry and Behavioral Sciences, Stanford Center for Neuroscience in Women’s HealthStanford University School of MedicineStanfordUSA
  2. 2.Department of Molecular and Medical PharmacologyUniversity of CaliforniaLos AngelesUSA
  3. 3.UCLA Center on Aging, Memory & Aging Research Center, Jane & Terry Semel Institute for Neuroscience & Human BehaviorUniversity of CaliforniaLos AngelesUSA

Personalised recommendations